Blocking the WNT/β-catenin pathway at the level of ligand secretion or enhancing β-catenin destruction in colorectal cancers with APC mutations may not be the most effective strategies, as deregulated signaling is independent of pathway receptor engagement with ligands and the destruction complex assembly is already defective. This evidence concerns the gene APC and colorectal cancer.